ESIMS - An Ongoing Clinical Trial in Secondary Progressive Multiple Sclerosis

Abstract

The design of a double-blind, placebo-controlled, European-Canadian Study on IVIG treatment in multiple sclerosis-ESIMS- is described. Three hundred and eighteen multiple sclerosis patients with a secondary progressive course, are treated with monthly infusions of immunoglobulin 10% I g/kg bodyweight or with 0.1 g albumin/vial for 27 months. The primary efficacy parameter is the percentage of patients with a confirmed treatment failure in the EDSS scale and/or the Nine Hole Peg Test Secondary outcome measures are MRI T2 lesion load, Magnetization Transfer Imaging, and MRI brainatrophy measures. Documentation of health resource utilisation and ability to work will cover socio-economic aspects. Recruitment of patients was completed in October 1998. The clinical part of the trial will be completed in April 2001.

Keywords

treatment secondary progressive MS immunoglobulin

Get full access to this article

View all access options for this article.

References

Rothfelder

, Neu

, Pelka

(1982) Therapy of Multiple) Sclerosis with immunoglobulin G. MMW Munch Med Wochenschr 124: 74–78.

Schullor

, Govaerts

(1983) First results of immunotherapy with immunoglobulin G in Multiple Sclerosis patients. Ear Neurol 22: 205–212.

Pascalidou

Long term therapeutic trial of MS patients using gammaglobulin: A two years follow-up. Proceedings 10th congress of the European Committee for Treatment and Research in Multiple Sclerosis. Athens (1994) p 204.

Cook

(1995) Intravenous gamma globulin in progressive MS. Acta Neurol Scand 86: 171 – 175.

Achiron

(1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting Multiple Sclerosis. Arch Neurol 49: 1233–1236.

Maidn

, Schwaighofer

Long-term therapy with high-dose IV immunoglobulins in MS. Clinical and MRI observations. Proceedings 10th congres of the European Committee for Treatment and Research in Multiple Sclerosis. Athens (1994) p 94.

Achiron

(1995) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in Multiple Sclerosis-a pilot study. J. Neuroimmunol (Suppl 1): 56.

Achiron

(1998) Intravenous immunoglobulin treatment in Multiple Sclerosis. Effect on relapses. Neurology 50: 398–402.

Poehlau

(1997) Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive Multiple Sclerosis - outline of a double-blind randomized, placebo-controlled trial. Multiple Sclerosis 3: 149–152.

10.

Fazekas

(1997) Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting Multiple Sclerosis. Lancet 349: 589 – 593.

11.

S-Sørensen

(1998) Intravenous immunoglobulin G reduces MRI activity in relapsing Multiple Sclerosis. Neurology 50: 1273–1281.

12.

Kurtzke

(1983) Rating neurologic impairment in multiple sclerosis-an expanded disability status scale (EDSS). Neurology 33: 1444–1452.

13.

Goodkin

(1991) EDSS reliability (letter). Neurology 41: 332.

14.

Weinshenker

, Issa

, Baskorville

(1996) Metaanalysis of the placebo-treated group in clinical trials of progressive MS. Neurology 46: 1013–1619.

15.

Rudick

(1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 42: 379–382.

16.

Cella

, Dineen

, Arnason

(1996) Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47; 129–139.

17.

Gass (1994) Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 36: 62–67.